I was really surprised on the recent action. Shows you that if there is action in a pharma stock, it attracts a lot of attention. Once the stock went up 20-40%, several others joined in on the action. It would be nice to know if pharma companies joined in that rally, since Rexahn is so cheap to buy. If they go over 5% they have to report it; so far that hasn't happened.
The press release that triggered this was nice, but the outcome of that new compound is so far off, that it can't be the only reason we rallied. I think it was a combination of the PR, and Archexin for Pancreatic being close to reporting its phase II results, with the latter being significant if positive. My thoughts are that the results will be positive because they just applied for Archexin for Ovarian cancer. I don't think they would have done that if the Pancreatic results were poor. They can't afford to do that because they are low on funds, and they have so many other compounds that they can promote. Plus, they made no mention of doing this in their "Goals for 2012" that they released months ago.
The Archexin for Pancreatic cancer results could be any day, since the study on the FDA site says July as the expected completion for all outcomes.
Market Data 
Markets 
AI
